An Acquired Defect in IgG-Dependent Phagocytosis Explains the Impairment in Antibody-Mediated Cellular Depletion in Lupus
- 1 October 2011
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 187 (7) , 3888-3894
Abstract
B cells play important roles in autoimmune diseases ranging from multiple sclerosis to rheumatoid arthritis. B cells have also long been considered central players in systemic lupus erythematosus. However, anti-CD20–mediated B cell depletion was not effective in two clinical lupus studies, whereas anti-B lymphocyte stimulator, which inhibits B cell survival, was effective. Others and we previously found that anti-CD20–based depletion was surprisingly ineffective in tissues of lupus-prone mice, but that persistent high doses eventually led to depletion and ameliorated lupus. Lupus patients might also have incomplete depletion, as suggested in several studies, and which could have led to therapeutic failure. In this study, we investigated the mechanism of resistance to Ab-mediated cellular depletion in murine lupus. B cells from lupus-prone mice were easily depleted when transferred into normal environments or in lupus-prone mice that lacked serum Ig. Serum from lupus-prone mice transferred depletion resistance, with the active component being IgG. Because depletion is FcγR-dependent, we assayed macrophages and neutrophils exposed to lupus mouse serum, showing that they are impaired in IgG-mediated phagocytosis. We conclude that depletion resistance is an acquired, reversible phagocytic defect depending on exposure to lupus serum IgG. These results have implications for optimizing and monitoring cellular depletion therapy.Keywords
This publication has 47 references indexed in Scilit:
- Prolonged effects of short‐term anti‐CD20 B cell depletion therapy in murine systemic lupus erythematosusArthritis & Rheumatism, 2010
- B cells as therapeutic targets in SLENature Reviews Rheumatology, 2010
- HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2010
- Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trialArthritis & Rheumatism, 2009
- Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with RituximabEuropean Journal of Immunology, 2007
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- Immune complex-degradation ability of macrophages in MKL/Mp-lpr/lprlupus mice and its regulation by cytokinesClinical and Experimental Immunology, 1994
- A rheumatoid factor transgenic mouse model of autoantibody regulationInternational Immunology, 1993
- Studies of peritoneal macrophage function in mice with systemic lupus erythematosus: Depressed phagocytosis of opsonized sheep erythrocytes in vitroClinical Immunology and Immunopathology, 1983
- Defective Reticuloendothelial System Fc-Receptor Function in Systemic Lupus ErythematosusNew England Journal of Medicine, 1979